Immune cell therapy for advanced bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests an investigational treatment using your own immune cells (called gamma-delta T cells) to fight advanced bladder cancer. It is for people whose cancer has not responded to at least two standard treatments and who cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have bladder cancer that cannot be removed by surgery and has continued to grow after at least two standard treatments.
- Your cancer is stage III or IV and you have at least one tumor that can be measured on scans.
- You are generally able to care for yourself (ECOG score of 0 or 1) and doctors expect you to live at least 6 more months.
- Your heart, liver, kidneys, and blood counts are within acceptable ranges based on blood tests and a heart ultrasound.
- You are not pregnant or nursing, and if you could have children, you agree to use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Hear when a new Advanced Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.